Ab­b­Vie puts an end to Botox trade se­crets suit, im­pos­es roy­al­ty, li­cense deal on com­peti­tor Evo­lus

The crown jew­el of Ab­b­Vie’s big-dol­lar ac­qui­si­tion of Al­ler­gan, Botox is one of the most rec­og­niz­able brands in phar­ma — and both drug­mak­ers have worked over­time to pro­tect its ad­van­tage. Af­ter scor­ing a fa­tal blow to Evo­lus’ chances as a ma­jor com­peti­tor late last year, Ab­b­Vie is now putting the ic­ing on the cake.

Look­ing to set­tle once and for all a years-long IP spat, Ab­b­Vie will put a lega­cy Botox trade se­crets case against Evo­lus to rest in re­turn for a roy­al­ty and li­cense deal for fu­ture sales, the Illi­nois drug gi­ant said Fri­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER